February 18, 2025
DEA, HHS Finalize Expansion of Buprenorphine Treatment via Telemedicine
The Drug Enforcement Administration (DEA) and the U.S. Department of Health & Human Services (HHS) are amending their regulations to expand the circumstances under which practitioners registered by the DEA are authorized to prescribe schedule III-V controlled substances approved by the FDA for the treatment of opioid use disorder via telemedicine, including an audio-only telemedicine encounter.
Under these new regulations, after a practitioner reviews the patient’s prescription drug monitoring program data for the state in which the patient is located, the practitioner may prescribe an initial six-month supply of such medications (split amongst several prescriptions totaling six calendar months) through audio-only means.
Click Here to Learn More